LRRC15 targeted therapy(NovaRock Biotherapeutics)

N/A

Report date: 2023/11/30 10:03:27

Base Information

Drug NameLRRC15 targeted therapy(NovaRock Biotherapeutics)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionAnti-LRRC15
TargetsLeucine-rich repeat-containing protein 15
Therapy Area/IndicationsSolid tumoursSarcoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNovarock Biotherapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNovarock Biotherapeutics Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursSarcoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A